Founded by experienced maternal fetal medicine specialists and backed by institutional investors, INEX offers a range of validated tests and holds 49 key patents. Their services include diagnostic testing, clinical research, and infectious testing through their subsidiary iGene Laboratory. INEX has received various accolades and awards, including recognition from Frost & Sullivan, the World Intellectual Property Organization, and the Financial Times. They are dedicated to delivering precision healthcare for women in Asia, with a focus on developing technologies such as ovarian cancer cyst tests, liquid biopsy-based breast and ovarian cancer tests, and non-invasive prenatal tests. Additionally, INEX has been involved in COVID-19 testing and was a finalist in the Business Transformation of the Year award category at the British Chamber of Commerce Singapore Annual Business Awards in 2020.